Medical Reference Cards

github.com/alping/medical-reference-cards

Adrenal Venous Sampling

Introduction: Primary aldosteronism (PA) is more common than previously thought. Up to 15% of all hypertension is due to PA. PA can be caused by bilateral or unilateral hyperplasia, an adenoma, or by mutations in genes coding for enzymes involved in aldosterone (AS) synthesis. Adrenal venous sampling (AVS) is a procedure used to diagnose the source of the excess aldosterone (i.e. whether it is uni- or bilateral). Why is this important? Because unilateral PA is treated surgically, whereas bilateral PA is managed medically. AVS is, by far, the most reliable way of establishing the source of excess AS.

The procedure: With AVS, the difference between left and right adrenal AS excretion is measured by sampling blood from each adrenal vein (AV). This is more complicated than it sounds, mostly for anatomical reasons. The right adrenal vein is very short and originates directly from the inferior vena cava (IVC), making it very difficult to cannulate. The left AV originates from a common trunk with the inferior phrenic vein (IPV), which, in turn, originates from the left renal vein. The common trunk is easier to cannulate than the left AV itself, but dilution from the IPV must then be compensated for when interpreting the AS level (in the common trunk, left AV blood is mixed with IPV blood, which obviously has a lower AS concentration).

- Endocrinology -

Adrenal Venous Sampling

Execution: The **right AV**, **IVC**, and **left AV** are cannulated, and blood is sampled for analysis of **AS** and **cortisol** levels. The AVs are catheterized through the percutaneous femoral vein approach. Gentle contrast injections are used to verify the position of the catheter tip.

• Why is blood sampled from the IVC? Why is the cortisol level analyzed? Aren't we only interested in the AS levels? These questions are answered in the interpretation section.

Interpretation: Ultimately, we're interested in whether there's a significant difference between AS levels in the two adrenal veins. So why cannulate the IVC? Because comparing the right AV and IVC cortisol levels tells us whether or not the difficult cannulation was successful – the cortisol level should be ≥3 higher in the right AV. If this is the case, we can trust subsequent measurements.

Before AS levels are compared, we must account for dilution. This is done by dividing the AS level with the cortisol level in each AV – the ratio will be the same regardless of dilution. These **corrected** values (A/C ratios) are the ones used in the final comparison.

If the A/C ratio of one adrenal vein is ≥4 times higher than that of the other, the source of AS is unilateral and should be treated **surgically**.

- General -

C-ABCDE

Catastrophic bleeding / Cardiac arrest

Airways Check airway Thorax movement See, listen, feel Paradox. breathing? Stridor?

- 1. Chin lift/Jaw thrust
- 2. Naso/Oropharyngeal airway
- 3. Suction
- 4. Laryngeal mask airway
- 5. Intubation
- 6. Coniotomy

B Breathing Respiratory rate

Thorax movement Auscultation Cyanosis

- 1. Oxygen
- 2. Ventilation
- 3. Decompression
- 4. Chest tube

Circulation Colour (Pale)

Cold/Sweaty Pulse (Rad / Fem / Car) Abdomen/Pelvis

- 1. Tilt bed
- 2. Fluids (PVC, IO, CVC)
- 3. Vasoactive drugs (Adrenalin IM)

Disability AVPU/GCS

Pupils Movement of extrem.

- 1. Support ABC
- 2. Glucose
- Antidote

Exposure Check whole body

Prevent hypothermia Prevent further injury

- 1. Log roll
- 2. Warm blankets
- 3. Warm fluids

- General -SBAR

Situation Own name, title, and unit Patients name, sex, and age Patients social security / identification number Describe situation briefly I'm contacting you to ...

Background
Previous and current illness Relevant medical history **Allergies** Contagiousness

Assessment

A: Airway

B: Breathing, saturation

C: Heart rate, blood pressure

D: Consciousness, pain, oriented to time / place / person

E: Temperature, skin, colour, abdomen, urine production

Brief assessment

Recommendation
Immediate action (Care, monitoring, transfer, treatment) Further examinations (Radiology)

Time frame (How often...? How long...? Next contact...?)

Confirmation of communication

Questions / Agreement

- Laboratory -

Lab reference (Swe)

| Sys. | Component | Subgroup | Ref. interval | Unit |
|------|----------------|-------------------|---------------|--------|
| P/S | ALAT | Male | 0,15 – 1,1 | μkat/L |
| | | Female | 0,15 - 0,75 | μkat/L |
| P/S | ALP | | 0,60 - 1,8 | μkat/L |
| P/S | Amylas | | 0,40 - 2,0 | μkat/L |
| P/S | Albumin | 18 – 40 y. | 36 – 48 | g/L |
| | | 41 – 70 y. | 36 - 45 | g/L |
| | | >70 y. | 34 – 45 | g/L |
| P/S | ASAT | Male | 0,25 - 0,75 | μkat/L |
| | | Female | 0,25 - 0,60 | μkat/L |
| P/S | Bilirubin | | 5 – 25 | µmol/L |
| P/S | Calcium | | 2,15 - 2,50 | mmol/L |
| P/S | CK | Male 18 – 50 y. | 0,80 - 6,7 | μkat/L |
| | | Male >50 y. | 0,70 - 4,7 | μkat/L |
| | | Female | 0,60 - 3,5 | μkat/L |
| P/S | Fosfat | Female | 0,80 - 1,5 | mmol/L |
| | | Male 18 – 50 y. | 0,70 - 1,6 | mmol/L |
| | | Male >50 y. | 0,75 - 1,4 | mmol/L |
| fP | Glukos | | 4,2-6,3 | mmol/L |
| P/S | GT | Male 18 – 40 y. | 0,15-1,3 | μkat/L |
| | | Male >40 y. | 0,20 - 1,9 | μkat/L |
| | | Female 18 – 40 y. | 0,15-0,75 | μkat/L |
| | | Female >40 y. | 0,15-1,2 | μkat/L |
| P/S | Järn | | 9 – 34 | μmol/L |
| P/S | Järnmättnad | Male | 0,15-0,60 | |
| | | Female 18 – 50 y. | 0,10-0,50 | |
| | | Female >50 y. | 0,15-0,50 | |
| Р | Kalium | | 3,5 - 4,4 | mmol/L |
| S | Kalium | | 3,6-4,6 | mmol/L |
| P/S | Kolesterol | 18 – 30 y. | 2,9 - 6,1 | mmol/L |
| | | 31 – 50 y. | 3,3 - 6,9 | mmol/L |
| | | >50 y. | 3,9 - 7,8 | mmol/L |
| P/S | HDL-Kolesterol | Female | 1,0-2,7 | mmol/L |
| | | Male | 0,80 - 2,1 | mmol/L |
| | | | | |

- Laboratory -

Lab reference (Swe)

| Sys. | Component | Subgroup | Ref. interval | Unit |
|------|----------------|-------------------|---------------|--------|
| P/S | LDL-Kolesterol | 18 – 30 y. | 1,2 – 4,3 | mmol/L |
| | | 31 – 50 y. | 1,4 - 4,7 | mmol/L |
| | | >50 y. | 2,0-5,3 | mmol/L |
| P/S | Kreatinin | Male | 60 – 105 | µmol/L |
| | | Female | 45 – 90 | µmol/L |
| P/S | LD | 18 – 70 y. | 1,8 - 3,4 | μkat/L |
| | | >70 y. | 1,9 – 4,2 | μkat/L |
| P/S | Magnesium | | 0,70 - 0,95 | mmol/L |
| P/S | Natrium | | 137 – 145 | mmol/L |
| P/S | Pankreasamylas | | 0,15 - 1,10 | μkat/L |
| P/S | Protein | | 64 – 79 | g/L |
| P/S | TIBC | | 47 – 80 | µmol/L |
| P/S | Triglycerider | | 0,45 - 2,6 | mmol/L |
| P/S | Urat | Male | 230 – 480 | µmol/L |
| | | Female 18 – 50 y. | 155 – 350 | µmol/L |
| | | Female >50 y. | 155 – 400 | µmol/L |
| P/S | Urea | Male 18 – 50 y. | 3,2 - 8,1 | mmol/L |
| | | Male >50 y. | 3,5 - 8,2 | mmol/L |
| | | Female 18 – 50 y. | 2,6-6,4 | mmol/L |
| | | Female >50 y. | 3,1 - 7,9 | mmol/L |
| В | Hemoglobin | Female | 117 – 153 | g/L |
| | | Male | 134 – 170 | g/L |
| В | EVF | Female | 0,350 - 0,458 | |
| | | Male | 0,393 - 0,501 | |
| В | Erytrocyter | Female | 3,94 - 5,16 | 1012/L |
| | | Male | 4,25 - 5,71 | 1012/L |
| В | MCV | | 82 – 98 | fL |
| Erc | MCH | | 27,1 - 33,3 | pg |
| Erc | MCHC | | 317 – 357 | g/L |
| В | Leukocyter | | 3,5 - 8,8 | 109/L |
| В | Trombocyter | Female | 165 – 387 | 109/L |
| | | Male | 145 – 348 | 109/L |

- Medicine - CHA2DS2VAS

| С | Cardiac - Heart failure | 1 |
|---|-------------------------------------|---|
| Н | Hypertension | 1 |
| A | Age ≥ 75 years | 2 |
| D | Diabetes | 1 |
| S | Stroke/TIA/embolism | 2 |
| V | Vascular Atherosclerotic disease | 1 |
| A | Age 65-74 | 1 |
| S | Sex - Female* | 1 |

^{*}No indication for antithrombotic treatment if only risk factor

AF and score ≥2 → Antithrombotic treatment *IF* low-medium risk of bleeding (HAS-BLED <3)

See local guidelines for specific antithrombotic drugs

Example of initial Warfarin treatment, 2.5mgx1 p.o.

Day 1: 2-4 | Day 2: 2-3 | Day 3: 1-4 (dep. on INR)


- Medicine - HAS-BLED

| Н | Hypertension >160 mmHg | 1 |
|---|--|-----|
| A | Abnormal liver or kidney function* | 1-2 |
| S | Stroke | 1 |
| В | Bleeding Previous tendency or anaemia | 1 |
| L | Labile INR High/unstable INR or <60% time in therapeutic range | 1 |
| Ε | Elderly (>65 years) | 1 |
| D | Drugs E.g. ASA, NSAID or high alcohol consumption | 1-2 |

^{*} Kidney: Creatinine >200, dialysis, or transplant Liver: Chronic liver disease, Bilirubin 2x ref, or ALAT/ASAT/ALP 3x ref.

High risk of bleeding if ≥3 points

Dermatomes



- Neurology - **Myotomes**

| Segment | Function |
|------------|--|
| C1/C2 | Neck flexion/extension |
| С3 | Neck lateral flexion |
| C4 | Shoulder elevation |
| C5 | Shoulder abduction |
| C6 | Elbow flexion/wrist extension |
| C 7 | Elbow extension/wrist flexion |
| C8 | Finger flexion |
| T1 | Finger abduction |
| L2 | Hip flexion |
| L3 | Knee extension |
| L4 | Ankle dorsi-flexion |
| L5 | Great toe extension |
| S1 | Ankle plantar-flexion/ankle eversion/ hip extension |
| S2 | Knee flexion |
| S3-S4 | Anal wink |

Neurological exam.

Higher cerebral functions

Wakefulness, oriented to time/place/self, comprehension, attention, spatial function, dysarthria, dysphasia, dyslexia, dyspraxia, neglect, amnesia, right or left handed

Standing

| | Symmetry | Strength |
|------|-------------------|------------------|
| Walk | Pattern | Squat and rise |
| | Normal/Toes/Heels | Jump on one leg |
| | Arm movements | Coordination |
| | Step length | Romberg's test |
| | Turning | Finger nose test |
| | | |

Sensory: Visual acuity, hearing

Sitting

| se. | Fundus examination (papillary stasis) Visual field (Donder's test) Movement (nystagmus, paresis, diplopia) | 9 | Symmetry Facial expressions Sensibility |
|-------|---|-------|--|
| Ē | Pupil (symmetry, size, reaction to light) Corneal reflex | Fa | Motor function Ptosis |
| Tests | Muscle strength (arm/finger/shoulder) Reflexes (brach.rad/bic/tric/patel./achill.) Grasset's test Dysdiadochokinesis, finger play | Mouth | Symmetry Tongue motor function Swallow reflex Gingival hyperplasia |

Lying down

Important: Neck stiffness

| | Jortant. Nook Juni1000 | | |
|--------|--------------------------------|----------|-----------------|
| es | Strength – proximal, distal | > | Light touch |
| | Tonus* – hand/elbow/knee joint | sibility | Vibration |
| nscles | Atrophies | Sib | Temperature |
| ₽ | Fasciculation | eu | Pain |
| _ | Tremor | တ | Proprioception |
| | Heel-knee test | ă | Grasping reflex |
| Tests | Reverse Barré's test | reflex | Glabellar |
| Ĕ | Straight leg raise | Ë | Palmomental |
| | Babinski's sign | ř | Sucking |

^{*}Rigidity, gear phenomenon, spasticity

- Neurology -

Glasgow Coma Scale

| | Respone | Score |
|-------------------------|-------------------------------------|-------|
| bu e | Spontaneously | 4 |
| Eye opening response | To speech | 3 |
| e op | To pain | 2 |
| Д | No response | 1 |
| | Oriented to time, place, and person | 5 |
| rbal Ise | Confused | 4 |
| Best verbal response | Inappropriate words | 3 |
| Bes | Incomprehensible sounds | 2 |
| | No response | 1 |
| | Obeys commands | 6 |
| <u>-</u> | Moves to localized pain | 5 |
| Best motor response | Flexion withdrawal from pain | 4 |
| est i esp | Abnormal flexion (decorticate) | 3 |
| Μ̈́ | Abnormal extension (decerebrate) | 2 |
| | No response | 1 |
| – ø | Best response | 15 |
| Total score | Comatose patient | ≤8 |
| - ω | Totally unresponsive | 3 |

- Orthopedics -

Ottawa Ancle Rule

1 Pain around the malleolus AND

Palpation tenderness over the dorsal ridge of the lateral or medial malleus

OR

Inability of the foot to support four steps

2 Pain around the mid part of the foot AND

Palpation tenderness over the base of the 5th metatarsal bone OR the Navicular bone

OR

Inability of the foot to support four steps

X-ray of foot and lower leg if 1 or 2 are met

Otherwise: Elastic wrap, tape, possibly orthosis, information (proprioceptive exercises e.g. stand on one leg while brushing teeth)

Acute care (PRICE)

Protection, Rest, Ice, Compression, Elevation

Only applicable on adults (>18 years) with isolated injury

- Orthopedics -

Well's DVT Score

| Sign | Point |
|---|-------|
| Active cancer last 6 months | 1р |
| Paralysis, paresis, newly casted | 1p |
| Immobilized >3 d. or large surgery last 4 w. | 1p |
| Localized tenderness along the deep venous system | 1р |
| Whole leg swelling | 1p |
| Calf circumference >3 cm, compared to asymptomatic side | 1р |
| Pitting oedema on symptomatic side | 1p |
| Collateral flow in superficial veins (non-varicose) | 1р |
| Similar likelihood of alternative diagnosis | -2p |

Low points <2 + negative D-dimer = low probability for DVT

High points ≥2 → Ultrasound whole leg

Risk of false negative D-dimer when symptoms >1w or anticoagulation therapy

Distal Status - Hand

Inspection

Hematomas / Wounds

Malalignment / Tonus

Palpation

Fossa tabatière

Distal radioulnar joint

Circulation

Allen's test - Ulnar / Radial loss of circulation

Capillary refill Dig I-V

Passive movement (tendons)

Finger extension, each separately

Flexor digitorum superficilais et profundus, separately

Neurology

1. Radialis 2. Medianus 3. Ulnaris

Sensory

- 1. Dig I, radially
- 2. Dig II, distal of PIP
- 3. Dig V, ulnar side
- 1. Extension of fingers
- 2. Opposition, Dig I & V
- 3. F.spread / Dig V flex.

Motor

Stability

Dig I, MCP, UCL, Distal radioulnar joint

Watson's test - Instability, scaphiodeum - lunatum

Specific tests

Tinel's and Phalen's tests: carpal tunnel syndrome

Finkelstein's test: Morbus de Quervain

Pain in wrist should result in plain film x-ray

- Orthopedics -
- Empty -

Normal Physiology

| Age | RR (/min) | HR (/min) | SBP (mmHg) |
|--------|-----------|-----------|------------|
| 0-1 m | 30-60 | 110-160 | 65-90 |
| 1-12 m | 30-40 | 110-160 | 70-90 |
| 1-2 y | 25-35 | 100-150 | 85-95 |
| 2-5 y | 25-30 | 95-140 | 80-110 |
| 5-12 y | 20-25 | 80-120 | 90-110 |
| >12 y | 15-20 | 60-100 | 100-120 |

| Age | ♀ W. (kg) | ♀ H. (cm) | ♂ W. (kg) | ♂ H. (cm) |
|------|------------------|-----------|-----------|-----------|
| 0 m | 2.8-4.2 | 46-54 | 2.9-4.4 | 47-55 |
| 3 m | 4.6-7.0 | 56-64 | 4.8-7.5 | 57-66 |
| 6 m | 6.0-9.3 | 62-71 | 6.4-10 | 63-73 |
| 1 y | 8.0-12 | 70-80 | 8.5-13 | 71-82 |
| 5 y | 15-25 | 102-120 | 15.5-25 | 110-112 |
| 18 y | 46-80 | 156-180 | 55-94 | 167-194 |

| Age (m) | 1-2 | 2-4 | 4-6 | 6-8 | 8-10 | 10-12 |
|---------------|-----|-----|-----|-----|------|-------|
| W. gain (g/w) | 175 | 150 | 125 | 100 | 75 | 50 |

| W. (kg) | | Fluids (ml/kg/24h) |
|--------------------|-------|--------------------|
| | 2-8 | 150 |
| | 6-10 | 115-120 |
| . | 0-10 | 100 |
| Holliday- Segar | 10-20 | 50 |
| ¥" | >20 | 20 |

| 74. (y) | iiii/kg/iioai |
|------------------|---------------|
| 0-1 | 2-4 |
| >1 | 1-2 |
| ▲ Urine | / Oliguri ▼ |
| 0-1 | <1 |
| >1 | <0.5 |

A (v) ml/kg/hour

Developmental Milestones

| Months | Gross motor | Fine motor | Cogn. & Comm. |
|--------|---|--|---|
| 1-2 | Lift head when prone | - | Smile in resp. to face/voice, visual preference for human face |
| 2-3 | Head steady in sitting | - | - |
| 3-4 | Lift head & chest w. ext. arms | Grasp rattle | Sustain contact, displeasure if soc. contact broken, "aah, ngah" |
| 5-6 | Roll over | Transfer objects hand to hand | Monosyllabic babble |
| 6-7 | Sit with support | - | Polysyllabic babble, vowel sounds, enjoys mirrors |
| 7-8 | Sit without support, crawl | Thumb- finger grasp | Suspicious/afraid of strangers |
| 9-10 | Pull to standing pos., walk holding furniture | Pincer grip, bang objects together. | Play peek-a-boo, wave bye-bye, respond to own name |
| 12-18 | Walk alone | Turn pages in book, scribble, build 2-cube tower | Speak a few words |
| 4 yrs. | Walk on a straight line, jump on one leg | Button clothes | Answer questions, understand prepositions |

Nutrition

| 0 - 4 | m | n | n | tŀ | 16 |
|-------|---|---|---|----|----|
| | | | | | |

Breast milk or formula

4-6 months

Breast milk or formula

Start to introduce small amounts of vegetables, cereals

6-8 months

Breast milk or formula or gruel or cereals

Complete meal (potatoes, meat, vegetables, fruit, berries)

Cow's milk can be used in cooking, but not as a beverage

8-12 months

Two cooked meals a day

From 10-12 months of age milk as a beverage

1-2 years

Regular food

No low-fat products and/or high-fibre foods

Vitamin D supplement

5 drops every day (400 IE/day)

All children from 1 month up to at least 2 years of age

Low intake/sun exposure may need suppl. till school age

Salt intake

No extra salt added to food for children below 1 year

Food items not suitable for children below 1 year

Spinach, mangold, and beetroot - high levels of nitrate Honey - may contain C. Botulinum spores

Apgar score

| Apgar Sign | 2 | 1 | 0 |
|---|---|---|------------------------------------|
| Heart Rate | >100/min | >100/min | Absent |
| Breathing Rate and effort | Cries well | Irregular | Absent |
| Grimace Responsiveness or reflex irritability | Pulls away, sneezes, coughs, or cries with stimulation | Facial movement only with stimulation | Absent |
| Activity Muscle tone | Active, spontaneous movement | Arms and legs flexed with little movement | No movement, floppy tone |
| Appearance Skin colouration | Normal colour (also hands and feet are pink) | Normal colour (but hands and feet are bluish) | Bluish-grey or pale all over |

This test is done to determine whether a newborn needs help breathing or is having heart trouble

Normal Results: 7-10

10 is unusual, almost all newborns lose 1 point for blue hands and feet

Abnormal results: 0-6

Signals that the baby needs medical attention

Low Apgar score is often caused by:

Difficult birth, C-section, Fluid in the baby's airway

A baby with a low Apgar score may need:

- Oxygen and clearing out the airway to help with breathing
- Physical stimulation to get the heart beating at a healthy rate

Most of the time, a low score at 1 minute is near-normal by 5 minutes

A lower Apgar score does not mean a child will have serious or long-term health problems

The Apgar score is not designed to predict the future health of the child

Vaccinations (Swe)

| Age | Vaccination | Dose |
|------------------|---|----------|
| 3 m | Diphtheria, Tetanus, Pertussis, Polio, Hib, S. Pneumoniae | I |
| 5 m | Diphtheria, Tetanus, Pertussis, Polio, Hib, S. Pneumoniae | II |
| 12 m | Diphtheria, Tetanus, Pertussis, Polio, Hib, S. Pneumoniae | III |
| 18 m | Measles, Mumps, Rubella | 1 |
| 5–6 y | Diphtheria, Tetanus, Pertussis, Polio | IV |
| 6–8 y | Measles, Mumps, Rubella | II |
| 10–12 y | HPV (girls born 1999 or later) | 1,11,111 |
| 14–16 y | Diphtheria, Tetanus, Pertussis | V |
| Risk patients | | - |

Barn födda till och med 2001 följer ett annat schema från 5-6 års ålder

Check-ups (Swe)

| Age | Profession | Assessment/Action |
|---------|----------------|---|
| 0-10 d | Nurse | Home visit |
| 2-8 w | Nurse | Growth assessment and counselling, once a week |
| 6-8 w | Doctor, nurse | Psychomotor development |
| 3 m | Nurse | Vaccination |
| 3-5 m | Nurse | Growth assessment and counselling, every other week |
| 5 m | Nurse | Vaccination |
| 6 m | Doctor | Check-up |
| 6-12 m | Nurse | Growth assessment and counselling, once a month |
| 10/12 m | Doctor | Check-up |
| 12 m | Nurse, dentist | Vaccination Dental health care information |
| 18 m | Nurse | Vaccination |
| 3 у | Nurse | Language development Child security information |
| 4 y | Nurse | Vision, hearing, language, and psychomotor development Child security information |
| 5.5 y | Doctor, nurse | Vaccination School assessment Child security information |

- Pharmacology -

Addiction

| | Drug | Half-life | Equivalent dose (mg) |
|-------------|------------------------|---------------|----------------------|
| | Oxazepam (Sobril) | Short | 15.0 - 25.0 |
| ts | Zopiklon / Zolpidem | Short / Short | 7.5 / 10.0 |
| <u>le</u> u | Nitrazepam (Mogadon) | Short | 2.5 |
| Equivalents | Lorazepam (Temesta) | Short | 1.0 |
| ᇟ | Flunitrazepam | Short | 0.5 |
| _ | Alprazolam (Xobril) | Short | 0.25-0.5 |
| Benzo. | Triazolam (Halcion) | Short | 0.25 |
| Be | Diazepam (Stesolid) | Long | 5.0 |
| | Klonazepam (Iktorivil) | Long | 0.25 |

| Be | Diazepam (Stesolid) | Long | 5.0 | | |
|-----------------|--|----------------|--------------------------|--|--|
| | Klonazepam (Iktorivil) | Long | 0.25 | | |
| | | | | | |
| Prir | nciples for dose-lowering | 3 | | | |
| S | Change drug to equivalent dose of | Oxazepam (S | Sobril) | | |
| pine | Split previous total daily dose into 5 | evenly distrib | outed doses over one day | | |
| iaze | Decrease total daily dose by 10% per week | | | | |
| poz | Start by reducing the middle-of-the-day dose, leave morning/evening till last | | | | |
| Benzodiazepines | Never increase the dose! If there is an increase of withdrawal symptoms, stay on the current dose until the symptoms have stabilised | | | | |
| | Change drug to equivalent dose of Kodein (Citodon) | | | | |
| | Split previous total daily dose into 5 evenly distributed doses over one day | | | | |
| ds | Decrease total daily dose by 20% / week | | | | |
| Opiods | Start by reducing the middle-of-the-day dose, leave morning/evening till last | | | | |
| O | Never increase the dose! If there is an increase of withdrawal symptoms, stay on the current dose until the symptoms have stabilised | | | | |
| | When only 4 pills left, terminate treatment | | | | |

- Pharmacology -
- Empty -